War Of Words: Pfizer Battles With Top Indian Pharma Lobby On Key Policy Issues
This article was originally published in PharmAsia News
Executive Summary
Pfizer counters assertions by the Indian Pharmaceutical Alliance that the U.S. company misled a congressional hearing about India’s deteriorating IP environment. With hard-hitting statements coming from both sides, the gloves have come off.